A director at Tikehau Capital bought 15,745 shares at 17.261EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
We downgrade TKO to Neutral ahead of Thursday’s strategic update. We expect management to revise mid term targets, potentially implying mid to high single digit downside to current consensus forecasts. We set a new target price of € 17.5.
Maxeda : les porteurs ayant rejoint l’accord de recapitalisation représentent 95% de l’obligation|Les titres participatifs (TP) bancaires font l’objet d’une modification de loi|PBB a publié 2 semaines en avance des résultats inférieurs aux attentes et un warning pour 2026/27|
A director at Elior Group sold 500,000 shares at 2.822EUR and the significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
Transgene Announces Financial Calendar for 2026 Strasbourg, France, February 4, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG) a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its financial reporting and Annual shareholders’ meeting dates for 2026: March 24, 2026: 2025 Fiscal Year Results April 29, 2026: First Quarter 2026 Financial Results May 13, 2026: Annual Shareholders’ Meeting September 24, 2026: First Half 2026 Financial Results November 9, 2026: ...
Transgene présente son calendrier de communication financière pour 2026 Strasbourg (France), le 4 février 2026, 17 h 45 – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies reposant sur des vecteurs viraux contre les cancers, annonce aujourd'hui son calendrier de communication financière pour 2026 et la date de son Assemblée générale annuelle : 24 mars 2026 : Résultats annuels de l’exercice 2025 29 avril 2026 : Résultats financiers du premier trimestre 2026 13 mai 2026 : Assembl...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.